This week, we hosted the second CSHL meeting on Fundamental Immunology & Its Therapeutic Potential and chatted with Fiona Powrie, a returning organizer for the meeting. During our conversation, Fiona mentioned the extensive dialogue among attendees around cancer immunology; and in fact: The number of oral sessions related to cancer immunology has doubled since the last iteration of the meeting in 2015.
There's been a real buzz around the place and a lot of exciting data presented. One of the features of this meeting that's different from the other meetings in this area...is that we've had a large number of early-stage scientists who've just set up their labs presenting really new data that has stimulated a lot of discussion from the PhD students and postdocs.
There's been a lot of discussion actually - and you can't stop immunologists talking so there is always a lot of discussion - around new insights in cancer immunology and how we recognize pathogens. There was a very interesting section in regulatory T-cells with some new findings about their specificity, how they're functioning, how they're selected. Of course, that opens up a lot of new avenues across the area of autoimmune and infectious diseases.